APOE and Alzheimer disease: Neuropathological studies showed increased AD-related neurofibrillary changes even in young APOE ε4-carriers [mean age, 38 years; age range, 22 to 46 years; (8)], which may speak in favor of the interpretation that impaired PI performance is a result of very early AD-related changes.